The massive equity raise creates a significant near-term overhang; expect downward pressure on DFTX as the market absorbs the 23.7 million new shares. Monitor for any acquisition or partnership announcement that may explain the accelerated capital raise, and watch insider trading patterns after the 60-day lock-up expires.
Price Chart
Executive Summary
Definium Therapeutics priced an upsized underwritten public offering of 20,588,236 common shares at $34.00 per share, with the underwriters fully exercising their option to purchase an additional 3,088,235 shares. Gross proceeds are expected to be approximately $805 million, with net proceeds of approximately $758 million after underwriting discounts and expenses. The offering, expected to close June 25, 2026, will fund R&D, potential commercialization of DT120 ODT, and working capital, but dilutes existing shareholders by roughly 22%.
Key Facts
- 20,588,236 common shares offered at $34.00 per share; underwriters' option for 3,088,235 additional shares exercised in full
- Gross proceeds ~$805 million; net proceeds ~$758 million after underwriting discounts and estimated expenses
- Offering expected to close June 25, 2026; shares priced at a ~6% discount to last sale of $36.18
- Proceeds to be used for R&D, preparation activities for potential commercialization of DT120 ODT, and working capital
- Directors and executive officers subject to a 60-day lock-up from the date of the underwriting agreement
Financial Impact
Dilution of approximately 22% based on 109,066,783 shares outstanding as of April 15, 2026; net proceeds of ~$758 million added to cash position
Risk Factors
- Substantial dilution (~22%) to existing shareholders from the upsized offering
- Potential for further equity raises if cash burn accelerates or if DT120 ODT commercialization requires more capital
- Execution risk on DT120 ODT regulatory approval and commercial launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-077354 |
| Document: tm2618395d3_8k.htm | 0001104659-26-077354 |
| Document: tm2618395d3_ex99-2.htm | 0001104659-26-077354 |
| Document: tm2618395d3_ex99-1.htm | 0001104659-26-077354 |
| Document: tm2618395d3_ex5-1.htm | 0001104659-26-077354 |
| Document: 0001104659-26-077354-index-headers.html | 0001104659-26-077354 |
| Document: 0001104659-26-077354-index.html | 0001104659-26-077354 |
| Document: 0001104659-26-077354.txt | 0001104659-26-077354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $40.25 $39.28 | ▼ −2.41% | ▼ −2.52% | $37.40 (−7.08%) |
Aug 12, 2026 7w ago | 8-K | $42.79 $45.82 | ▲ +7.08% | ▲ +7.53% | $37.40 (−12.60%) |
Aug 9, 2026 7w ago | Institutional Cluster | $45.15 $45.26 | ▲ +0.24% | ▲ +0.29% | $37.40 (−17.17%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 24, 2026 14w ago | 8-K | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 24, 2026 14w ago | 424B5 | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 22, 2026 14w ago | 424B5 | $36.18 $46.55 | ▼ −28.66% | ▼ −27.65% | $37.40 (−3.37%) |
Apr 27, 2026 22w ago | DEFA14A | $21.27 $21.75 | ▲ +2.26% | ▲ +0.56% | $37.40 (+75.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access